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Glycemic regulation improves myocardial function in diabetic pa-
tients, but finding optimal therapeutic strategies remains challenging.
Recent data have shown that pharmacological inhibition of soluble
epoxide hydrolase (sEH), an enzyme that decreases the endogenous
levels of protective epoxyeicosatrienoic acids (EETs), improves glu-
cose homeostasis in insulin-resistant mice. Here, we tested whether
the administration of sEH inhibitors preserves cardiac myocyte struc-
ture and function in hyperglycemic rats. University of California-
Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood
glucose levels in the range of 150–200 mg/dl were treated with the sEH
inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk.
Administration of APAU attenuated the progressive increase of blood
glucose concentration and preserved mitochondrial structure and
myofibril morphology in cardiac myocytes, as revealed by electron
microscopy imaging. Fluorescence microscopy with Ca2 indicators
also showed a 40% improvement of cardiac Ca2 transients in treated
rats. Sarcoplasmic reticulum Ca2 content was decreased in both
treated and untreated rats compared with control rats. However,
treatment limited this reduction by 30%, suggesting that APAU may
protect the intracellular Ca2 effector system. Using Western blot
analysis on cardiac myocyte lysates, we found less downregulation of
sarco(endo)plasmic reticulum Ca2-ATPase (SERCA), the main route
of Ca2 reuptake in the sarcoplasmic reticulum, and lower expression of
hypertrophic markers in treated versus untreated UCD-T2DM rats. In
conclusion, APAU enhances the therapeutic effects of EETs, resulting in
slower progression of hyperglycemia, efficient protection of myocyte
structure, and reduced Ca2 dysregulation and SERCA remodeling in
hyperglycemic rats. The results suggest that sEH/EETs may be an
effective therapeutic target for cardioprotection in insulin resistance and
diabetes.
arachidonic acid pathway; hyperglycemia; diabetes; insulin resis-
tance; calcium
HYPERGLYCEMIA is a major risk factor for the development of
insulin resistance, type 2 diabetes mellitus (T2DM), and car-
diovascular disease (CVD) (30). High blood glucose can dam-
age the vasculature and affect heart structure and function
(3–5, 8, 24, 46, 54). Hyperglycemia can also trigger inflam-
mation and hypertension, which also contribute to CVD pa-
thology (3–5, 8, 24, 30, 46, 54). The transition to T2DM
generally accelerates pathological changes of the cardiovascu-
lar system (3–5, 8, 24, 30, 46, 54). Therefore, effective thera-
peutic strategies to limit or prevent CVD in patients with
hyperglycemia require the control of blood glucose, blood
pressure, and inflammation. Epoxyeicosatrienoic acids (EETs)
are signaling molecules implicated in the modulation of blood
pressure (25–28, 51), inflammatory cascades (22, 26, 27, 51),
and glucose homeostasis (37, 38). Hence, controlling the en-
dogenous levels of EETs appears as an effective strategy to
protect the cardiovascular system against glucotoxicity. This
can be achieved by preventing their degradation (27, 51) or
through dietary supplementation. Intriguingly, dietary supple-
mentation with docosahexaenoic acid (DHA), a naturally de-
rived counterpart, improved mitochondrial function in the
hypertrophied myocardium (31, 53). Apparently, EETs and
DHA underlie similar mechanisms of cardioprotection that
involve the activation of sarcolemmal and mitochondrial ATP-
sensitive K channels (35, 52).
Degradation of EETs can generally be prevented by inhib-
iting soluble epoxide hydrolase (sEH), an enzyme that converts
EETs to dihydroxyeicosatrienoic acids (DHETs) (27, 51).
Treatment with sEH inhibitors has demonstrated beneficial
effects in animal models of high blood pressure (25, 26, 28),
inflammation (10, 22, 26), myocardial injury (1, 23, 26, 41),
ischemia-reperfusion (49, 50), pathological cardiac hypertro-
phy (26), and insulin resistance (37, 38). Hyperglycemic mice
treated with sEH inhibitors showed improved insulin signaling
and sensitivity (37, 38). On the basis that EETs appear to
control biological processes that may be fundamental to car-
dioprotection, we hypothesized that modulating the endoge-
nous levels of EETs using sEH inhibitors may protect the heart
against structural and functional alterations induced by hyper-
glycemia. To test this hypothesis, we examined the structure
and function of cardiac myocytes isolated from hyperglycemic
rats treated with a sEH inhibitor versus untreated and nor-
moglycemic, control rats. As an indicator of myocyte function,
we measured Ca2 cycling. Intracellular Ca2 concentration
([Ca2]i) is central to cardiac myocyte contractility and viabil-
ity, and dysregulation of [Ca2]i plays an important role in the
pathophysiology of heart disease (6), including diabetic cardiac
disease (19, 32, 40, 45).
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METHODS
In the present study, we used a rat model of hyperglycemia to test
whether the inhibition of sEH can prevent molecular and cellular
alterations of the myocardium.
Experimental animals. This investigation conformed with the Na-
tional Institutes of Health Guide for the Care and Use of Laboratory
Animals (NIH Pub. No. 85-23, Revised 1996) and was approved by
the Institutional Animal Care and Use Committee of the University of
California-Davis (UCD). For this study, we used the UCD-T2DM rat
model of T2DM, which was obtained by breeding obese Sprague-
Dawley rats with Zucker diabetic lean rats. UCD-T2DM rats exhibit
polygenic adult onset obesity, insulin resistance, and inadequate
pancreatic -cell compensation, followed by the transition to hyper-
glycemia and T2DM (14, 15). Diabetes incidence, age of onset,
longitudinal measurements of glucose, insulin, and lipids, and glucose
tolerance were previously reported in Ref. 15. Data showing blunted
insulin signaling, including Akt phosphorylation, in the liver, skeletal
muscle, and adipose tissue in diabetic UCD-T2DM rats were reported
in Ref. 14. Additional studies using the UCD-T2DM rat model to
investigate the pharmacological and surgical treatment and prevention
of T2DM were previously published in Refs. 14, 16, and 17. Here,
nonfasting blood glucose concentrations were measured weekly start-
ing at 2 mo of age. When the nonfasting blood glucose concentration
was in the range of 150–200 mg/dl (8.3–11.1 mM) for two consec-
utive readings, rats were considered in a prediabetic stage. A total of
20 prediabetic male rats (15  2 wk of age) were enrolled in this
study, and a total of 10 age-matched male Sprague-Dawley rats
(Charles Rivers Laboratory) were used as nondiabetic controls.
Sprague-Dawley rats (Charles River Laboratory) were chosen as
control animals since these animals were crossed to Zucker diabetic
lean rats to generate the original UCD-T2DM rat model (15).
Treatment. Four prediabetic UCD-T2DM rats were euthanized
before treatment. Cardiac myocytes isolated from these rats were
examined for function and structure. In the present study, we used
1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) (UC1153,
AR9281), a sEH inhibitor made using the methods of Jones et al. (29).
Treatment with APAU improved endothelial function in animal mod-
els of T2DM, obesity, and hypertension (57). Rats in the sEH inhibitor
treatment group (n  10, 15  2 wk old) received 1 ml APAU per
liter of drinking water for 6 wk, starting from the onset of the
prediabetic state. APAU was formulated in polypropylene glycol at a
concentration of 10 mg/l with 30-min sonication and then added to
drinking water at a final concentration of 10 mg/l. Rats had unre-
stricted access to water. Prediabetic rats in the untreated group (n 
6, 15  2 wk old) received the same amount of polyethylene glycol,
a neutral biocompatible polymer. Nonfasting blood glucose concen-
trations were measured weekly (morning time) in all rats with a
glucometer (One Touch Blood Glucose Meter, LifeScan). One rat
from the sEH inhibitor treatment group was found dead after 3 wk of
treatment. No obvious symptoms of sickness were noticed in the
behavior of the rat. At the end of the treatment period, rats were
euthanized for cardiac myocyte isolation and subsequent functional
and structural measurements.
Blood levels of APAU were assessed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) in a subset of treated and
control rats and ranged from 180 to 1,300 ng/ml, far in excess of what
is required to inhibit the enzyme [IC50  2 ng/ml or 6 nM (55)]. The
compound was not detected in control samples. APAU intake varied
with blood glucose concentrations. Diabetic rats with blood glucose
levels  500 mg/dl received 5 mg·kg1·day1 APAU and diabetic
rats with blood glucose levels in the range of 200–500 mg/dl received
3 mg·kg1·day1, whereas diabetic rats with blood glucose levels in
the domain of 200–300 mg/dl as well as nondiabetic rats with blood
glucose levels 	 200 mg/dl received 1 mg·kg1·day1. This is
likely due to proportionally increased water intake as a result of
hyperglycemia. Indeed, water intake increased from 43 ml/day for
nondiabetic rats to 150 ml/day for diabetic rats with blood glucose
levels between 200 and 300 mg/dl and 250 ml/day for diabetic rats
with blood glucose above 500 mg/dl.
EET level measurements. Analysis of EETs and their diols,
DHETs, was performed by LC-MS/MS as previously described (58).
Briefly, an Agilent 1200 SL LC series (Agilent, Palo Alto, CA) and an
Agilent Eclipse Plus C18 2.1 
 150-mm, 1.8-m column were used
for EET separation. The mobile phase A was water with 0.1% acetic
acid, whereas the mobile phase B was composed of acetonitrile-
methanol [80:15 (vol/vol)] and 0.1% acetic acid. Gradient elution was
performed at a flow rate of 250 l/min. The injection volume was 10
l, and the samples were kept at 4°C in the autosampler. Analytes
were detected by negative MRM mode using a 4000 QTrap tandem
mass spectrometer (Applied Biosystems Instrument, Foster City, CA)
equipped with an electrospray ionization source (Turbo V). Calibra-
tion curves were generated by 10-l injections of seven standards
containing each analyte, internal standard I, and internal standard II
for quantification purposes. Measurements were done of pancreas
protein homogenates.
Cardiac myocyte isolation. Rats were anesthetized by an intraperi-
toneal injection of pentobarbital (1 mg/g) and monitored for com-
plete loss of reflexes, which was verified by firm foot pinch or loss of
the blink reflex. When deep anesthesia was reached, hearts were
quickly excised, placed on a Langendorff perfusion apparatus, and
perfused with 1 mg/ml collagenase (18). When the heart became
flaccid, the left ventricular tissue was cut into small pieces, dispersed,
and filtered (18). The standard Tyrode solution used in these experi-
ments contained (in mM) 140 NaCl, 4 KCl, 1 MgCl2, 10 glucose, 5
HEPES, and 1 CaCl2 (pH 7.4). All experiments were done at room
temperature (23–25°C).
Transmission electron microscopy. For electron microscopy imag-
ing (21), cardiac myocytes were isolated from treated (n  4),
untreated (n  4), and healthy control (n  4) rats and gently pelleted
using a benchtop centrifuge (Eppendorf Centrifuge 5415D) operated
for 3 min at 2,000 rpm. The pelleted samples were then loaded into
200-m deep copper specimen carriers and rapidly frozen using a
Leica EM-PACT2 high-pressure freezer. Frozen samples were then
freeze substituted at 90°C for 50 h in anhydrous acetone containing
0.2% glutaraldehyde and 0.1% uranyl acetate using a Leica EM AFS
device. Frozen samples were subsequently raised to 40°C at a rate
of 5°C/h, kept at 40°C for 12 h, and warmed to 20°C at a rate of
10°C/h for infiltration and embedding in Eponate-12 resin with
DMP-30 accelerator (Ted Pella). Resin-embedded samples were po-
lymerized by heating at 70°C for 72 h, and blocks containing cardiac
myocytes were cut into 70-nm-thick sections using a Leica Ultracut T
microtome equipped with a Diatome 45° diamond knife. Serial sec-
tions were collected on slot grids covered with a 50-nm Formvar
support film. Before being imaged, sections were poststained with 2%
uranyl acetate in 70% methanol for 4 min. Grids were visualized on
a transmission electron microscope (JEM-1230, JEOL) operated at
120 keV. Images of each section were recorded at 2-m defocus on
a 2,048 
 2,048-pixel charge-coupled device camera (TVIPS, Gaut-
ing, Germany) and at nominal magnifications of either 
1,000 or

2,500, yielding an effective pixel size of 11 or 4.4 nm, respectively.
Intracellular Ca2 measurements. Myocytes were plated on laminin-
coated coverslips, mounted on the stage of a fluorescence microscope,
and loaded with fluo-4 AM (10 mol/l). Fluo-4 was excited at 488
nm, and fluorescence was collected at 535  30 nm. Ca2 transients
were elicited by field stimulation at frequencies between 0.2 and 2 Hz.
Data are expressed as F/F0, where F0 is the fluorescence signal in
resting myocytes and F is the measured fluorescence signal, to make
the signal independent of the amount of dye loaded into myocytes. F0
was measured for each cell during a stop in the pacing before the
application of 10 mM caffeine (see Fig. 5A). Such normalization
works only as long as resting [Ca2]i at which F0 is measured is
similar between groups. Initial tests (not shown) with the ratiometric
indicator fura-2 revealed that resting [Ca2]i is indeed similar in
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myocytes from control and diabetic UCD-T2DM rats (untreated).
Thus, we used diastolic fluo-4 F/F0 as a measure of diastolic [Ca2]i
and the difference between F/F0 measured at systole and diastole as
Ca2 transient amplitude.
Immunochemistry. Isolated cardiac myocytes were lysed, and sam-
ples were centrifuged at 3,500 rpm to remove cellular components.
Standard Western blot experiments were performed. Membranes were
probed with primary antibodies against brain natriuretic peptide (BNP;
Millipore), sarco(endo)plasmic reticulum Ca2-ATPase (SERCA; clone
2A7-A1, ABR), total phospholamban (PLB; Badrilla), PLB phosphory-
lated at Ser16 (Badrilla), and Na/Ca2 exchanger (NCX, Millipore) as
well as mitochondrial fission protein 1 (Fis1), dynamin-related protein 1
(DRP1), mitofusin 2 (Mfn2), and optic atrophy 1 (OPA1; all from Santa
Cruz Biotechnology). Equal loading was verified by reprobing with
anti-GAPDH (Thermo Scientific Pierce Antibodies).
Statistical analysis. Data are expressed as means  SE. Statistical
discriminations were performed using a two-tailed unpaired Student’s
t-test when two groups were compared, one-way ANOVA with
Bonferroni’s post hoc test when multiple groups were compared, and
two-way ANOVA when multiple groups for multiple conditions were
compared (as in Figs. 1, 4, A and C, and 5, C and F). P values of
	0.05 were considered significant.
RESULTS
We assessed the course of blood glucose levels in treated
versus untreated and control animals during the 6-wk treatment
period. At the end of treatment, we examined cardiac myocyte
morphology, Ca2 cycling, and the level of expression of Ca2
cycling proteins in all rats.
APAU improved glucose metabolism. The study was initi-
ated when rats were in a prediabetic state, characterized by
nonfasting blood glucose levels in the range of 150–200 mg/dl
(8.3–11.1 mM) for two consecutive readings. Body mass was
comparable for rats in the treated and untreated groups, both at
the time of study initiation (572 11 g for the untreated group
vs. 562  14 g for the treatment group) and after the 6 wk of
treatment (572 11 g for the untreated group vs. 596 8 g for
the treatment group). Two weeks after study initiation, all
UCD-T2DM rats in the untreated group showed overt hyper-
glycemia and developed T2DM (nonfasting blood glucose
level  200mg/dl or 11.1 mM; Fig. 1). In contrast, the
progression to hyperglycemia was considerably slower in
APAU-treated UCD-T2DM rats (Fig. 1). Only half of the rats
in the APAU treatment group had nonfasting blood glucose
levels of 200 mg/dl (11.1 mM) and developed T2DM during
the first 3 wk of treatment. In time, the inadequate pancreatic
-cell compensation in UCD-T2DM rats overcame the bene-
ficial effects of APAU, leading to overt hyperglycemia. Thus,
80% of APAU-treated rats had developed diabetes at the end of
the 6 wk of treatment. However, even the final blood glucose
reading at the end of treatment was still significantly lower in
treated versus untreated rats (Fig. 1). To assess the effect of
APAU treatment on EET levels, we measured EETs and their
corresponding diols, DHETs, in the pancreas from treated and
untreated rats. There was a large increase of EETs in APAU-
treated versus untreated rats (Table 1). Therefore, the EET-to-
DHET ratio was greatly elevated in treated rats.
APAU reduced the structural alteration of cardiac myocytes.
Ultrastructural examination of cardiac myocytes using serial
section transmission electron microscopy (TEM) revealed that
APAU could reduce hyperglycemia-mediated molecular alter-
ations in the heart (Fig. 2). Cardiac myocytes from control rats
has ellipsoidal-shaped mitochondria that were well organized
into long, one mitochondrion-thick, continuous tracts nestled
between adjacent myofibrils (Fig. 2, A and D). Myocytes from
UCD-T2DM rats in the untreated group showed the altered
mitochondrial morphology and mitochondrial fragmentation
and clustering (Fig. 2, B and E) typical of cardiac dysfunction
(13, 42–44). Mitochondrial fragmentation and clustering
seemed to adversely affect the normal ultrastructure of adjacent
myofibrils, as evidenced by the vertical shift of the Z-lines
shown in Fig. 2E. In contrast, the majority of the mitochondria
in myocytes from the APAU-treated group (Fig. 2, C and F)
retained an ellipsoidal shape and were found in long, one
mitochondrion-thick, continuous chains typical of rats in the
control group. However, occasional mitochondrial clustering
(white arrowhead in Fig. 2C) and myofibrillar disarray were
also found in some myocytes from the APAU-treated group.
We used automated contour modeling (Fig. 2, G–I) to measure the
surface area of individual mitochondria and fat vacuoles from
TEM images of myocytes from control, treated, and untreated
groups. This analysis revealed larger individual fat vacuoles in
myocytes from untreated UCD-T2DM rats compared with both
control rats and treated UCD-T2DM rats (Fig. 3A). However,
the total area occupied by fat vacuoles was similar in myocytes
Table 1. Levels of EETs and inactive DHETs in the
pancreas in untreated and 1-(1-acetypiperidin-4-yl)-3-
adamantanylurea-treated rats
Treated Group Untreated Group
EETs, ng/g protein
14,15-EET 958 151 114  9*
11,12-EET 786 181 109  14
8,9-EET 354 56 44  11*
5,6-EET 1,737 169 361  53*
DHETs, ng/g protein
14,15-DHET 10.8 4.3 5.7  1.6
11,12-DHET 16.5 1.6 8.9  0.7*
8,9-DHET 22.3 5.5 21.7  4.9
5,6-DHET 6.6 2.0 4.2  1.7
Values are means  SE. EET, epoxyeicosatrienoic acid; DHET, dihy-
droxyeicosatrienoic acid. *P 	 0.05.
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Fig. 1. 1-(1-Acetypiperidin-4-yl)-3-adamantanylurea (APAU) treatment atten-
uated the escalation of blood glucose levels in University of California-Davis
(UCD)-type 2 diabetes mellitus (T2DM) rats. Blood glucose was measured
weekly for the 6-wk treatment period (n  9 APAU-treated rats, 6 untreated
UCD-T2DM rats, and 10 nondiabetic control rats). ***P 	 0.001 vs. the
control group; ###P 	 0.001 vs. the treated group (by two-way ANOVA).
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from treated and untreated rats and was larger than in control
rats (Fig. 3A). The average size of cardiac mitochondria from
untreated UCD-T2DM rats was significantly smaller than in
control rats (Fig. 3B). However, the percentage of the cell
occupied by mitochondria was similar (Fig. 3B). These data
indicate mitochondrial fragmentation in myocytes from un-
treated UCD-T2DM rats. In contrast, cardiac mitochondria
from treated UCD-T2DM rats had an average size similar to
control rats (Fig. 3B). To further investigate this, we deter-
mined the expression level of two proteins associated with
mitochondrial fission: mitochondrial Fis1 and DRP1. Both
proteins were upregulated in untreated but not treated diabetic
UCD-T2DM rats (Fig. 3, C and D). Surprisingly, the expres-
sion of Mfn2 and OPA1, proteins associated with mitochon-
drial fusion, was elevated in both treated and untreated UCD-
T2DM rats versus control rats (Fig. 3, C and D). This suggests
an increased turnover of mitochondrial fission and fusion
processes in myocytes from untreated UCD-T2DM rats, which,
as indicated by the TEM data, results in mitochondrial frag-
mentation.
APAU reduced the alteration of cardiac Ca2 cycling in hyper-
glycemic rats. [Ca2]i is central to cardiac myocyte contractility
and viability (6). [Ca2]i dysregulation plays an important role
in the pathophysiology of heart disease (6), including diabetic
cardiomyopathy (19, 32, 40, 45). Thus, we examined Ca2
cycling in cardiac myocytes from age-matched treated and
untreated UCD-T2DM rats and age-matched, healthy control
rats.
2.5µm 2.5µm 2.5µm
1µm 1µm 1µm
Control Untreated Treated
HG I
Fig. 2. Ultrastructural analysis of cardiac myocytes. A–F: transmission electron micrographs of isolated cardiac myocytes from control rats (A and D), untreated
diabetic UCD-T2DM rats (B and E), and diabetic rats treated with soluble epoxide hydrolase inhibitor (C and F). Scale bars  2.5 m in A–C and 1.0 m in
D–F. White arrows in A and C indicate long, single tracks of mitochondria. White arrowheads in B and C indicate short, agglomerated mitochondria tracks. White
arrows in D indicate the Z-lines for adjacent sarcomeres of a myofibril. The black arrow in D points to a single mitochondrion, and the white arrowhead indicates
a fat deposit. G–I: contours for mitochondria (green) and fat vacuoles (red) in the images from D–F.
H856 sEH INHIBITION PROVIDES CARDIOPROTECTION IN DIABETIC RATS
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00154.2012 • www.ajpheart.org
 at Univ of California at Davis on M
arch 20, 2013
http://ajpheart.physiology.org/
D
ow
nloaded from
 
Ca2 transients were measured using the fluorescent indica-
tor fluo-4 (Figs. 4 and 5). Myocytes were paced at 0.2, 0.5, 1,
and 2 Hz until Ca2 transients reached steady state (Fig. 5A).
Pacing was then stopped for 10 s, and we applied 10 mM
caffeine to empty the sarcoplasmic reticulum (SR) of Ca2.
The amplitude of the caffeine-induced Ca2 transient was used
as a measure of SR Ca2 content. At the start of APAU
treatment, Ca2 transient amplitude (Fig. 4A) and decay time
(Fig. 4B) and diastolic [Ca2]i (Fig. 4C) measured in cardiac
myocytes from UCD-T2DM rats were similar to control, non-
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Fig. 4. Ca2 transient characteristics are unaltered in UCD-T2DM rats at start
of APAU treatment. A: Ca2 transient amplitude in cardiac myocytes from
prediabetic UCD-T2DM rats and control, nondiabetic rats. F/F0, measured
fluorescence signal (F)/fluorescence signal in resting myocytes (F0). B: Ca2
transient decay time () in myocytes from prediabetic (pre-DM) UCD-T2DM
rats and control, nondiabetic rats. C: diastolic intracellular Ca2 concentration
([Ca2]i) in myocytes from prediabetic UCD-T2DM rats and control, nondi-
abetic rats. n 20 myocytes from 4 different animals/group. The rats used had
an average age of 15  2 wk.
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Fig. 3. Larger fat vacuoles and mitochondrial fragmentation in myocytes from
untreated UCD-T2DM rats. A: average surface area of individual fat vacuoles (left)
and the percent area they occupy (right) in myocytes from control (Ctrl), treated,
and untreated rats. B: average surface area of individual mitochondria (left) and
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Data in A and B were calculated from the transmission electron microscopy images. C
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diabetic rats. Hence, the slight rise of blood glucose did not
alter cardiac myocyte Ca2 regulation in prediabetic UCD-
T2DM rats.
At the late T2DM stage, Ca2 transients and SR Ca2
content are drastically reduced, resulting in repressed contrac-
tility of the heart (32, 40, 45). This is generally attributed to the
impaired glucose and lipid homeostasis in combination with
vascular factors that lead to major cardiac remodeling (3, 4, 5,
8, 24, 30, 54). Indeed, cardiac myocytes isolated from UCD-
T2DM rats that were not treated with APAU and therefore
developed rapidly overt hyperglycemia (Fig. 1) had reduced
Ca2 transient amplitude (Fig. 4, B and C) and SR Ca2
content (Fig. 5E), which are indicative of systolic heart dys-
function. Treatment with APAU partially prevented the reduc-
tion in both Ca2 transient amplitude (by 40%; Fig. 4, B and
C) and SR Ca2 content (by 30%; Fig. 5E). In contrast to
cardiac myocytes from control rats, myocytes from hypergly-
cemic UCD-T2DM rats showed a negative force-frequency
relationship, particularly at higher stimulation frequencies (Fig.
5C). Treated and untreated UCD-T2DM rats did not show any
alterations in Ca2 transient relaxation (Fig. 5D) and diastolic
Ca2 (Fig. 5F), indicating normal diastolic function at this
early stage of disease development.
APAU limited the pathological remodeling of cardiac myo-
cytes in hyperglycemic rats. Alterations in the function and/or
expression of proteins involved in Ca2 cycling, particularly
SERCA (11, 32, 40, 45), have been reported in various T2DM
rodent models (11, 32, 40, 45). At the initial time point, before
the start of the treatment, UCD-T2DM rats showed unaltered
expression of SERCA (Fig. 6A). The development of overt
hyperglycemia in untreated UCD-T2DM rats led to cardiac
SERCA downregulation (Fig. 6, C and D), which may explain
the reduction in SR Ca2 content noted above (Fig. 5E).
SERCA downregulation is a common occurrence in diabetic
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Fig. 5. APAU treatment partially prevents the
decrease in Ca2 transient amplitude and sar-
coplasmic reticulum (SR) Ca2 content in
UCD-T2DM rats. A: representative example
of Ca2 transient and SR Ca2 content mea-
surements. Fluo-4 -loaded cardiac myocytes
were paced with external electrodes at 0.2,
0.5, 1, and 2 Hz until Ca2 transients reached
steady state. After 2 Hz, pacing was stopped
for 10 s, and we applied 10 mM caffeine to
measure SR Ca2 content. B: representative ex-
amples of Ca2 transients in myocytes from
nondiabetic control rats, untreated UCD-T2DM
rats, and UCD-T2DM rats treated with APAU.
Myocytes were paced at 0.5 Hz. C–F: mean
Ca2 transient amplitude (C), Ca2 transient
decay time (D), SR Ca2 content (E), and dia-
stolic [Ca2]i in cardiac myocytes from nondi-
abetic control rats, untreated UCD-T2DM rats,
and UCD-T2DM rats treated with APAU. n 
20 myocytes from 4 different animals/group.
Measurements were done at the end of the 6-wk
treatment period. *P 	 0.05 and ***P 	 0.001
vs. the control group unless otherwise indicated.
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cardiomyopathy (46). Treatment with APAU partially limited
the reduction in SERCA expression (Fig. 6, C and D), in
agreement with its effect of mitigating the decrease in SR Ca2
content. Intriguingly, APAU treatment favored an increase in
NCX protein expression, the main route of Ca2 extrusion
(Fig. 6, C and D). Total expression of PLB, an endogenous
SERCA inhibitor, was similar in all groups. However, more
PLB was phosphorylated at Ser16 in the untreated group.
Since PLB phosphorylation relieves SERCA inhibition, the
increased PLB phosphorylation may, in part, mitigate the
functional effect of SERCA downregulation.
APAU attenuated the expression of BNP in hyperglycemic
UCD-T2DM rats. Increased natriuretic peptide levels are gen-
erally thought to reflect cardiac dysfunction and have been
used as a “biomarker” of cardiac hypertrophy (20, 36, 48). The
BNP level in cardiac myocytes from UCD-T2DM rats at the
initial point of treatment was similar to control rats (Fig. 6B).
However, the BNP level was four times higher in hearts from
hyperglycemic UCD-T2DM rats versus age-matched control
rats (Fig. 6D). This suggests hormonal alterations specific to
the onset of cardiac hypertrophy in UCD-T2DM hyperglyce-
mic rats. APAU treatment lowered the BNP level by 30%,
suggesting that the APAU-mediated cardioprotection may in-
volve BNP signaling events, as suggested by recent work (12).
DISCUSSION
UCD-T2DM rats in the untreated group progressed rapidly
to overt T2DM (Fig. 1) and demonstrated cardiac dysfunction
at the cellular level, as shown by altered myocyte structure
(Figs. 2 and 3), smaller Ca2 transients and SR Ca2 load (Fig.
5), myocyte remodeling (Fig. 6B), and prohypertrophic protein
expression (Fig. 6). Inhibition of sEH slowed the development
of T2DM (Fig. 1) and limited the morphological alterations of
cardiac myocytes (Figs. 2 and 3), Ca2 mishandling (Fig. 5),
pathological remodeling of SERCA (Fig. 6D), and BNP ex-
pression (Fig. 6, C and D) in APAU-treated rats.
TEM micrographs showed altered mitochondrial morphol-
ogy and mitochondrial fragmentation and clustering, typical
for heart disease (13, 42–44), in myocytes from untreated
UCD-T2DM rats. In agreement with this, we found elevated
expression of proteins implicated in both mitochondrial fission
and fusion, which suggests an increased turnover of these
processes in hearts from the untreated group. APAU treatment
alleviated mitochondrial fragmentation. In myocytes from the
APAU-treated group, the majority of the mitochondria retained an
ellipsoidal shape and the average size of the mitochondria and
expression level of mitochondrial fission proteins were similar to
the control group.
Ca2 transient relaxation and diastolic Ca2 were not altered
in diabetic UCD-T2DM rats from either treated or untreated
groups. Combined with reduced Ca2 transient amplitude, this
suggests that, in diabetic UCD-T2DM rats, systolic dysfunc-
tion occurs in the absence of diastolic dysfunction. This is
somewhat surprising since in several other diabetic rodent
models, including our T2DM rat model expressing human
amylin (19), diastolic dysfunction precedes systolic dysfunc-
tion (19, 40, 45, 9). We found reduced SERCA expression in
both treated and untreated diabetic UCD-T2DM rats. However,
in the untreated group, the functional effect of SERCA down-
regulation may be mitigated by increased PLB phosphorylation
at the Ser16 site, which disinhibits the existing SERCA pumps. In
contrast, treated UCD-T2DM rats showed elevated NCX levels,
which may also compensate for the reduction in SERCA.
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Fig. 6. APAU treatment mitigates the reduction in sarco(endo)plasmic reticu-
lum Ca2-ATPase (SERCA) expression and the increase in brain natriuretic
peptide (BNP) level in hearts from UCD-T2DM rats. A and B: at the time that
APAU treatment was started (time 0 in Fig. 1), SERCA (A) and BNP (B) levels
in hearts from UCD-T2DM rats [prediabetic (PD)] were similar to those in
hearts from control Sprague-Dawley rats. C and D: SERCA expression was
significantly reduced, whereas the BNP level was increased, in hearts from
both treated and untreated diabetic UCD-T2DM rats versus nondiabetic control
rats. However, APAU treatment alleviated both SERCA downregulation and
the increase in BNP expression. Phospholamban (PLB) expression was un-
changed, but more PLB was phosphorylated at Ser16 (PLB-S16) in the
untreated group. Na/Ca2 exchanger (NCX) was significantly elevated in the
APAU-treated group. C: representative examples; D: mean data. Western blots
were run at least 4 times, and equal loading was verified with GAPDH.
Measurements were done at the end of the 6-wk treatment period. *P 	 0.05;
**P 	 0.01; ***P 	 0.001.
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Mechanism of APAU-induced cardioprotection. The main
physiological role of sEH is to control the EET level, and
pharmacological sEH inhibition has previously been shown to
elevate EET blood levels (28). Indeed, we found significantly
increased EETs levels in APAU-treated versus untreated rats.
Thus, it is likely that the therapeutic effects of APAU observed
here are the result of increased endogenous levels of EETs,
which may elicit a multimodal mechanism of cardioprotection.
APAU treatment and genetic sEH deletion have been previ-
ously shown to enhance glucose-stimulated insulin secretion
and to improve insulin signaling and sensitivity in diabetic
mice (37, 38). Thus, both mechanisms may contribute to
reducing blood glucose levels in diabetic UCD-T2DM rats. It
is clear that the attenuated hyperglycemia (Fig. 1) may play an
important role in preserving cardiac myocyte structure (Fig. 2)
and Ca2 cycling (Fig. 5). On the other hand, EETs are
involved in the activation of sarcolemmal and mitochondrial
ATP-sensitive K channels (35, 52), a critical mechanism of
cardioprotection. Hence, APAU may induce a direct effect on
cardiac Ca2 handling (Fig. 5). The direct effect of EETs on
the activation of mitochondrial ATP-sensitive K channels
may also explain the well-preserved cardiac mitochondrial
structure in APAU-treated rats (Fig. 2). In addition, enhancing
the EET level can generate antihypertensive and antiinflam-
matory effects (10, 22, 23, 25, 26, 28, 51) that may lessen the
glucotoxicity on myocardial structure and function in APAU-
treated rats.
Untreated hyperglycemic UCD-T2DM rats showed hor-
monal alterations specific to the onset of cardiac hypertrophy,
as suggested by the increased BNP level (Fig. 6B). An increas-
ing amount of experimental data have indicated that sEH
inhibitors can attenuate cardiac hypertrophy (2, 34, 56). The
process may involve BNP signaling events, as recently sug-
gested (12). APAU-treated rats showed lower cardiac BNP
concentrations compared with untreated rats (Fig. 6C), indicat-
ing that the cardioprotection provided by sEH inhibitors may
indeed involve BNP signaling events.
While APAU seems a potent inhibitor of sEH, other sEH
inhibitors may elicit a much improved inhibitory effect (33,
55). The new generation of inhibitors displays superior phar-
macokinetics, absorption, distribution, metabolism, and excre-
tion compared with APAU (33, 47). Hence, the cardioprotec-
tion against hyperglycemia can significantly be improved by
using more potent sEH inhibitors. Nevertheless, the potency of
sEH inhibitors may vary when the compounds are assayed
against different mammalian sEH enzymes. For example,
APAU is more potent against mouse and rat enzymes than the
human enzyme and is a far weaker inhibitor of the canine
enzyme (29, 33, 55). Extension of this study to other animal
models of hyperglycemia and the use of other potent inhibitors
may prove useful in optimizing the treatment for translational
purposes.
Clinical relevance and study limitations. Hyperglycemia and
T2DM are independent risk factors for adverse cardiovascular
events. Clinical data have shown that a significant fraction of
patients with T2DM do not achieve the optimum glycemic
target goal (39). Although insulin treatment has been demon-
strated to improve mechanisms of vasodilation and atherogenic
lipid patterns and to reduce inflammatory markers predictive of
heart disease, the risk of cardiovascular events remains high.
Multimodal strategies to optimize glycemic control and pro-
vide cardioprotection across the phenotypic spectrum of dia-
betes are needed. Our study suggests that increasing the avail-
ability of endogenous EETs starting from prediabetes results in
a slower progression of hyperglycemia, efficient protection of
myocyte structure, and reduced Ca2 dysregulation and
SERCA remodeling in hyperglycemic rats. In the absence of a
group of APAU-treated control, nondiabetic rats, we cannot
determine whether this protection is mediated by attenuated
hyperglycemia or is the direct effect of increased EETs on the
heart. Further studies are also needed to assess the effective-
ness of APAU if treatment is started after the onset of T2DM.
The present results are limited by the lack of comparison of
cardiac myocyte structure and function in UCD-T2DM rats
treated with insulin.
In conclusion, pharmacological inhibition of sEH slows the
progression of hyperglycemia and provides cardioprotection in
a rat model of T2DM. The mechanisms by which sEH inhib-
itors can protect the heart from hyperglycemia seem to be
multimodal and likely involve improved glucose regulation
and direct actions on modulation of cardiac Ca2 cycling. sEH
could be an effective therapeutic target in the early stage of
disease development, before the onset of full-blown T2DM.
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